Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
|Articles|July 19, 2022
Daily Medication Pearl: Dalbavancin (Dalvance)
Author(s)Saro Arakelians, PharmD
Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.
Advertisement
Medication Pearl of the Day: Dalvance (dalbavancin)
Indication: Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Insight:
- Dosing: Two-dose regimen 1000 mg followed 1 week later by 500 mg.
- Dosage forms: For injection 500 mg of lyophilized powder in a single-use vial for reconstitution.
- Adverse events: The most common adverse reactions in patients treated with dalbavancin were nausea (5.5%), headache (4.7%), and diarrhea.
- Mechanism of action: Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.
Source:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5